Overview

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Pomalidomide
Thalidomide